Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Trinity Biotech (TRIB) Long-Term Debt Issuances (2020 - 2022)

Trinity Biotech recorded quarterly Long-Term Debt Issuances of $63000.0 in Q4 2022, down 99.92% quarter-over-quarter from $80.0 million in Q1 2022, and up 103.57% year-over-year from $30947.4 in Q4 2021.

Trinity Biotech's Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $63000.0 for Q4 2022.

  • In Q4 2022, Long-Term Debt Issuances rose 103.57% year-over-year to $63000.0; the TTM figure through Dec 2022 stood at $78.3 million (changed N/A YoY), while the FY2025 annual figure was $15.0 million, down 50.29% from the prior year.
  • Long-Term Debt Issuances came in at $63000.0 for Q4 2022 at Trinity Biotech, down from $80.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $80.0 million in Q1 2022 to a low of -$1.8 million in Q4 2021.
  • A 3-year average of $16.9 million and a median of $1.8 million in 2021 frame the typical range for Long-Term Debt Issuances.
  • On a YoY basis, Long-Term Debt Issuances climbed as much as 4436.0% in 2022 and fell as far as 103.57% in 2022.
  • Trinity Biotech's Long-Term Debt Issuances stood at $4.5 million in 2020, then slumped by 139.03% to -$1.8 million in 2021, then jumped by 103.57% to $63000.0 in 2022.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $63000.0, $80.0 million, and -$1.8 million for Q4 2022, Q1 2022, and Q4 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Trinity Biotech 28,000.00 -5.11 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 63,000.00
Dec 31, 2022 63,000.00
Mar 31, 2022 80.02 Mn
Mar 31, 2022 80.02 Mn
Dec 31, 2021 -1.76 Mn
Dec 31, 2021 -1.76 Mn
Mar 31, 2021 1.76 Mn
Mar 31, 2021 1.76 Mn
Jun 30, 2020 4.52 Mn
Jun 30, 2020 4.52 Mn